Head to Head Comparison: Cibus (NASDAQ:CBUS) versus Moolec Science (NASDAQ:MLEC)

Cibus (NASDAQ:CBUS) and Moolec Science (NASDAQ:MLEC) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Volatility and Risk

Cibus has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Moolec Science has a beta of -0.36, suggesting that its share price is 136% less volatile than the S&P 500.

Institutional and Insider Ownership

33.8% of Cibus shares are held by institutional investors. Comparatively, 0.1% of Moolec Science shares are held by institutional investors. 49.4% of Cibus shares are held by insiders. Comparatively, 19.9% of Moolec Science shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Cibus and Moolec Science”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64 million	31.15	-$127.08 million	($2.98)	-0.50
Moolec Science	$333.61 million	0.02	-$111.46 million	($33.00)	-0.25

Moolec Science has higher revenue and earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Moolec Science, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cibus and Moolec Science’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cibus	-3,492.30%	-174.58%	-29.48%
Moolec Science	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Cibus and Moolec Science, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1	1	1	0	2.00
Moolec Science	0	0	0	0	0.00

Cibus presently has a consensus target price of $9.00, suggesting a potential upside of 506.06%. Given Cibus’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Cibus is more favorable than Moolec Science.

Summary

Cibus beats Moolec Science on 8 of the 14 factors compared between the two stocks.

About Cibus

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

About Moolec Science

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.